5 employees
Ailomics Therapeutics focuses on developing innovative drugs to treat immune diseases and tumors.
2022
Ailomics Therapeutics raised undisclosed on May 31, 2023
Investors: Qiming Venture Partners
Ailomics Therapeutics raised undisclosed on August 9, 2022